Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 478
- Registration Number
- NCT05950516
- Locations
- 🇨🇳
Shandong Provincial Hospital, Jinan, Shandong, China
Effect of Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults with Obesity
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 65
- Registration Number
- NCT05933499
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
- Conditions
- Interventions
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 140
- Registration Number
- NCT05920889
- Locations
- 🇨🇳
Linyi People's Hospital, Linyi, Shangdong, China
🇭🇰Chinese University of Hong Kong, Hong Kong, Hong Kong
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT05891496
- Locations
- 🇮🇹
Fondazione Santa Lucia IRCCS, Roma, Italy
🇨🇦Memory Program, Toronto, Ontario, Canada
🇸🇪Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden
Semaglutide Therapy for Alcohol Reduction - Tulsa
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2023-11-07
- Target Recruit Count
- 80
- Registration Number
- NCT05891587
- Locations
- 🇺🇸
OSU Biomedical Imaging Center, Tulsa, Oklahoma, United States
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 230
- Registration Number
- NCT05890976
- Locations
- 🇨🇳
Peking University People's Hospital-Endocrinology, Beijing, Beijing, China
🇨🇳Beijing Friendship Hospital, Capital Medical University-Endocrinology, Beijing, Beijing, China
🇨🇳Huizhou Central People's Hospital-Endocrinology, Huizhou, Guangdong, China
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 360
- Registration Number
- NCT05877547
- Locations
- 🇺🇸
Indago Research & Health Center, Inc ( Site 3207), Hialeah, Florida, United States
🇺🇸Sweet Hope Research Specialty, Inc-Research ( Site 3200), Hialeah, Florida, United States
🇺🇸Velocity Clinical Research, Syracuse ( Site 3227), East Syracuse, New York, United States
Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 96
- Registration Number
- NCT05829460
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 751
- Registration Number
- NCT05822830
- Locations
- 🇺🇸
Southern California Dermatology, Inc., Santa Ana, California, United States
🇺🇸University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 60
- Registration Number
- NCT05822609
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇨🇦Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.